Here's why the Resapp (ASX:RAP) share price closed 5% lower

The Resapp (ASX: RAP) share price closed 5% lower today after the company reported a loss in first-half FY21 results. Here's a closer look.

| More on:
falling asx share price represented by woman making sad face

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resapp Health Ltd (ASX: RAP) share price spent today in the red after the company's 1HY21 results came out this morning.

Apparently, investors weren't impressed with the results and sent ResApp shares down 5.0% to close at 5.6 cents a share.

The company develops and commercialises its ResApp technology to provide healthcare solutions for respiratory disease. Let's review the results to decipher what pushed the ResApp share price down for the day.

ResApp Health posts first-half loss

For the period ended 31 December 2020, the healthcare solutions provider reported a net loss of $3.1 million compared to the $3.8 million loss posted for 1HY20.

ResApp's net asset position was $5.5 million.

At the end of 1HY21, ResApp Health's cash and cash equivalents totalled $4.2 million, a bump up from $3.9 million at the end of 1HY20.

Revenue totalled $46K and the company received $345,300 in government grants and tax incentives.

ResApp reported a 41 cent loss per share for 1HY21 compared to a 55 cent loss per share for 1HY20.

The company spent $1.7 million during 1HY21 on research and development activities pertaining to its medical technology. During 1HY20, it spent $2.8 million.

New appointment

ResApp also today advised the market that Mike Connell has been appointed as vice president (VP), commercial.

The company said Mr Connell brought extensive experience in sales, marketing and strategy across the industry. 

In his new position, he will process the company's growth strategy by pursuing a variety of international commercial activities. 

The company believes that Mr Connell's strong sector understanding and networks will present the business with new opportunities going forward.

During his time with GlaxoSmithKline (GSK),  Mr Connell launched and led GSK's European Established products business which delivered revenues totalling £3 billion during 2014.

He joins ResApp following time spent as general manager, corporate portfolio with Medibank.

About the ResApp share price

The ResApp share price has had a challenging past 12 months, crashing 74.5% over the period.

The company has a market capitalisation of $44.7 million and there are 758.1 million shares outstanding.

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »